Results 141 to 150 of about 478,784 (306)
How is Nanoarchitectonics Shaping Extracellular Vesicle Research?
Advanced Healthcare Materials, EarlyView.The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake +5 more
wiley +1 more source
Advanced Materials, EarlyView.Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi +3 more
wiley +1 more source
, 2010 Background: Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine kinase inhibitor (TKI) treatment.
高劍虹;張逸良;蔡孟峰;吳振都;余忠仁;楊志新;李元麒;楊泮池;施金元 +1 more
core +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
Intracrine Signaling by The Epidermal Growth Factor Receptor
, 2023 The epidermal growth factor receptor (EGFR) is a member of the erbB family of receptor tyrosine kinases. In our study, we were interested to study the intracrine signaling mechanism of the EGF receptor in cells expressing both EGFR and its ligand EGF and
Naceur, Razane
core
Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences
Advanced Science, EarlyView.This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu +7 more
wiley +1 more source
Synthetic Toll‐Like Receptors for Control of Innate Immunity With Far‐Red Light
Advanced Science, EarlyView.Synthetic Toll‐like receptors (TLRs) are engineered by replacing their natural sensing regions with a far‐red‐light‐responsive module from a bacterial phytochrome. These synthetic receptors enable light‐controlled regulation of immune signaling in mammalian cells.
Anna V. Leopold, Vladislav V. Verkhusha
wiley +1 more source
Advanced Science, EarlyView.Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
EGFR T790M: revealing the secrets of a gatekeeper
, 2017 Brian Ko, Daniel Paucar, Balazs Halmos Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA Abstract: Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent ...
Halmos B, Ko B, Paucar D
core
Second-Line Treatments after First-Line Gefitinib Therapy in Advanced Nonsmall Cell Lung Cancer
, 2011 Gefitinib is effective as first-line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second-line regimens could lead to better outcomes.
WU, JENN-YU;SHIH, JIN-YUAN;YANG, CHIH-HSIN;CHEN, KUAN-YU;HO, CHAO-CHI;YU, CHONG-JEN;YANG, PAN-CHYR +1 more
core +1 more source